Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Aug 31, 2018 3:47pm
290 Views
Post# 28550783

RE:lots of dumping

RE:lots of dumpingLots of dumping???
Volume is 121,295 
Hardly count that as lots, in fact it is very very small.
The problem has nothing to do with people selling, it's the opposite, no one is buying.
We need new blood. we need some new buyers. 

Or if anyone thought about this for a sec, investing 101 is buy low sell high.
Now is the time to be buying.
If nothing else someone could use this as a swing trade.
They said Part1 will comence this quarter (Fiscal Q2, 2019) that means less then 4 weeks away. Typicaly companies will always release more details before a trial starts like who they partnered with and such. This means we should expect a NR within 4 weeks (probably less). Also if they say they are starting a trial, that should give us a bump up in share price, easily 10% at this level (0.03) and probably more. You are thinking about buying this for the long haul or short term, this is a screaming buy at this level.

Just my two cents.

Bullboard Posts